Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodrigo E Mendes

Showing results (191-200 of 257) with videos related to

Pageof 26
Sort By:
Antimicrobial Agents and Chemotherapy|March 27, 2019
Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase ProducersRodrigo E Mendes, Mariana Castanheira, Leah N Woosley, et al.
International Journal of Antimicrobial Agents|February 4, 2023
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021)Helio S Sader, Rodrigo E Mendes, S J Ryan Arends, et al.
Journal of Clinical Microbiology|September 14, 2012
Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumoniaRodrigo E Mendes, Lalitagauri M Deshpande, Davida S Smyth, et al.
Diagnostic Microbiology and Infectious Disease|February 25, 2015
Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013Helio S Sader, David J Farrell, Rodrigo E Mendes, et al.
The Journal of Antimicrobial Chemotherapy|December 19, 2023
7-Year (2015-21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanismsSusanne Paukner, Rodrigo E Mendes, S J Ryan Arends, et al.
Antimicrobial Agents and Chemotherapy|March 29, 2017
Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant SubsetsRodrigo E Mendes, Mariana Castanheira, Leah N Woosley, et al.
Antimicrobial Agents and Chemotherapy|May 29, 2014
Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agentsRodrigo E Mendes, Donald Biek, Ian A Critchley, et al.
Journal of Global Antimicrobial Resistance|December 13, 2016
Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agentsRodrigo E Mendes, Mariana Castanheira, David J Farrell, et al.
Antimicrobial Agents and Chemotherapy|April 3, 2019
Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of OrganismsS J Ryan Arends, Paul R Rhomberg, Nicole Cotroneo, et al.
Diagnostic Microbiology and Infectious Disease|April 6, 2017
Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nationsRonald N Jones, Robert K Flamm, Mariana Castanheira, et al.
Pageof 26

Showing results (191-200 of 257) with videos related to

Sort By:
Pageof 26
Antimicrobial Agents and Chemotherapy|March 27, 2019
Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase ProducersRodrigo E Mendes, Mariana Castanheira, Leah N Woosley, et al.
International Journal of Antimicrobial Agents|February 4, 2023
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021)Helio S Sader, Rodrigo E Mendes, S J Ryan Arends, et al.
Journal of Clinical Microbiology|September 14, 2012
Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumoniaRodrigo E Mendes, Lalitagauri M Deshpande, Davida S Smyth, et al.
Diagnostic Microbiology and Infectious Disease|February 25, 2015
Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013Helio S Sader, David J Farrell, Rodrigo E Mendes, et al.
The Journal of Antimicrobial Chemotherapy|December 19, 2023
7-Year (2015-21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanismsSusanne Paukner, Rodrigo E Mendes, S J Ryan Arends, et al.
Antimicrobial Agents and Chemotherapy|March 29, 2017
Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant SubsetsRodrigo E Mendes, Mariana Castanheira, Leah N Woosley, et al.
Antimicrobial Agents and Chemotherapy|May 29, 2014
Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agentsRodrigo E Mendes, Donald Biek, Ian A Critchley, et al.
Journal of Global Antimicrobial Resistance|December 13, 2016
Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agentsRodrigo E Mendes, Mariana Castanheira, David J Farrell, et al.
Antimicrobial Agents and Chemotherapy|April 3, 2019
Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of OrganismsS J Ryan Arends, Paul R Rhomberg, Nicole Cotroneo, et al.
Diagnostic Microbiology and Infectious Disease|April 6, 2017
Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nationsRonald N Jones, Robert K Flamm, Mariana Castanheira, et al.
Pageof 26